March 20 (Reuters) - Bristol Myers Squibb said on Wednesday a combination of its drugs, Opdivo and Yervoy, met the main goal of a late-stage study evaluating it as a first-line treatment for a type of liver cancer. (Reporting by Puyaan Singh)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.3 USD | +1.45% | +1.27% | -13.75% |
11:25am | India's Alembic Pharma posts higher Q4 profit on strong N.America sales | RE |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.75% | 88.52B | |
+32.92% | 698B | |
+26.51% | 568B | |
-4.62% | 358B | |
+19.43% | 328B | |
+3.46% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.83% | 165B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol Myers liver cancer treatment meets main goal of late-stage study